Saturday, 31 October 2026European Markets

OREGE Stock Bullish By 21% So Far Today

Loading stream...

orege, a france-based industrial contaminants solutions company, made a remarkable recovery in the market today. the company's shares saw a significant increase of 21.96%, reaching a value of eur0.62. this notable rise follows a challenging period of five consecutive days of losses on wall street.

orege's stock surge and its implications

orege's stock surge did not mirror an overall market decline, as showcased by the cac 40's 1.14% fall to eur7,265.11. this suggests broad economic or industry factors influenced orege's performance. despite these adverse conditions, the company managed to defy the general market trends. notably, orege's stock price remains 37% lower than its 52-week high of eur0.82, alluding to a potential for further growth.

an evaluation of orege's profitability

orege reports an earnings per share (eps) figure of eur-0.12, indicating no profit made over the past year. this factor may serve as a warning signal about the company's profitability potential to potential investors.

market volatility and orege's performance

orege notably stands out in the market due to its stock volatility. over the last week, its stock experienced an average fluctuation of 5.63%, which rose to 4.82% during the third quarter. such a high degree of stock volatility can suggest investor speculation or market instability. concurrently, it presents opportunities to traders who thrive under rapidly changing market conditions.

forecasting orege's future performance

in conclusion, orege's recent surge in the stock market differs from general trends, signaling potential for future growth. however, its volatile market performance and negative profitability over the past year are factors that investors should carefully consider when making investment decisions.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com